Table 1.
Baseline clinicopathological of HBsAg+ and HBsAg- cohorts
| Factors | HBsAg+ (N=368) | HBsAg- (N=6742) | P |
|---|---|---|---|
| synCRLM (Yes/No) | 43/325 | 576/6166 | 0.037 |
| Gender (male/female) | 214/154 | 3975/2767 | 0.759 |
| Age (years, mean±SD) | 56.66±11.61 | 60.69±12.81 | 0.001 |
| Initial manifestation | |||
| Bleeding or blood in stool | 93 (25.27%) | 1702 (25.24%) | |
| Change in the consistency, size or shape of stools | 18 (4.89%) | 275 (4.08%) | |
| Change in frequency of bowel movements | 11 (2.99%) | 277 (4.11%) | |
| Abdominal pain or discomfort | 42 (11.41%) | 1103 (16.36%) | |
| Abdominal mass | 2 (0.54%) | 34 (0.50%) | |
| N/A or other initial manifestation | 202 (54.90%) | 3345 (49.62%) | |
| Asymptomatic colonoscopy exam (ACE) | 0 | 6 (0.09%) | 0.274 |
| synCRLM excluding ACE (Yes/No) | 43/325 | 576/6160 | 0.038 |
| Primary CRC | |||
| Tumor size (cm) | 4.71±2.00 | 4.74±2.04 | 0.852 |
| Location | |||
| Colon | 128 (34.78%) | 2357 (34.96%) | |
| Rectum | 129 (35.06%) | 2581 (38.28%) | 0.516 |
| N/A | 111 (30.16%) | 1804 (26.76%) | |
| Grade | |||
| Poorly | 59 (16.03%) | 961 (14.25%) | |
| Moderately | 256 (69.57%) | 4638 (68.79%) | |
| Well | 13 (3.53%) | 235 (3.49%) | 0.772 |
| N/A | 40 (10.87%) | 908 (13.47%) | |
| T stage | |||
| Tis-T2 | 55 (14.95%) | 1088 (16.14%) | |
| T3- T4 | 271 (73.64%) | 4634 (68.73%) | 0.336 |
| N/A | 42 (11.41%) | 1020 (15.13%) | |
| N stage | |||
| N0 | 194 (52.72%) | 3440 (51.02%) | |
| N1-N2 | 127 (34.51%) | 2211 (32.80%) | 0.876 |
| N/A | 47 (12.77%) | 1091 (16.18%) | |
| CEA (ng/ml) | 28.21±109.65 | 27.74±106.34 | 0.557 |
| CA199 (U/ml) | 55.81±144.66 | 55.64±235.67 | 0.001 |
HBsAg: hepatitis B surface antigen; synCRLM: synchronous colorectal liver metastasis; N/A: not available; Tis: tumor in situ; CEA: Carcinoembryonic Antigen; CA199: Carbohydrate Antigen 19-9.